Shifa International Approves Merger of Neuro Sciences Subsidiary

Shifa International Hospitals Limited (SIHL) has approved a merger plan to integrate its wholly owned subsidiary, Shifa Neuro Sciences Institute Islamabad (SNSI), into the parent company. The decision, made during a board meeting on February 22, 2025, is subject to the fulfillment of all contractual and regulatory requirements. SIHL will proceed with the merger of its wholly owned subsidiary company, Shifa Neuro Sciences Institute Islamabad (Private) Limited (SNSI), into SIHL (the Amalgamation). The Amalgamation would lead to inter alia a simplification of the corporate structure by eliminating redundant administrative layers and inter-company relationships. SIHL’s oversight, resources, and streamlined management will ensure that operations are more efficient, costs associated with maintaining separate entities are reduced, and compliance processes are simplified. The merger will also consolidate resources, enabling better asset utilization, improved financial reporting through unified statements, and centralized management of liabilities. Direct control over operations will enhance decision-making and productivity, while the single entity structure will facilitate future growth, ease capital raising, and strengthen market presence, ensuring the entity is well-positioned for expansion and long-term success. It will further increase the asset base and size of SIHL and as a result, SIHL will be in a position to effectively and efficiently benefit from economies of scale with respect to the combined business. Further business expansion opportunities for SIHL are also expected to arise due to this proposed amalgamation. The proposed Amalgamation would be subject to receipt of all requisite contractual, corporate and regulatory authorizations, consents, and approvals, the filing added.